Kymera Results Presentation Deck

● ● KT-474 Showed Meaningful Signs of Clinical Activity in AD, Comparing Favorably to Placebo Benchmarks and SOC Summary Results Mean EASI score reduction up to 37%, with maximum reduction of up to 76% Mean peak pruritus NRS reduction of 52 to 63% Peak pruritus NRS Responder rate of 57 to 71% Investigator Global Assessment (IGA) scores improved in 2 of 7 patients and remained stable in the others AEASI APeak Pruritus NRS KT-474 Part C -37% -52 to -63% Placebo Benchmarks Week 4 -12 to -25%* 57 to 71% -11%¹ Peak Pruritus NRS Responder *Range from 7 different Phase 2 and Phase 3 trials; **Range from 10 different Phase 2 and Phase 3 trials; ¹Simpson EL, et al. NEJM 2016;375:2335-2348; 2Bieber T, et al. NEJM 2021;384:1101-1112; The Dupilumab clinical trial was conducted by other parties in a similar patient population with different enrollment criteria from Part 1C of our Phase 1 clinical trial evaluating KT-474. Results do not reflect a head-to-head trial and are shown for illustrative purposes only KYMERA Ⓒ2022 KYMERA THERAPEUTICS, INC. ** Dupilumab Phase 3 Week 4 -52%¹ -34%¹ 4 to 17%* 23 to 40%¹,2 PAGE 50

View entire presentation